WoodTrust Financial Corp Sells 2,216 Shares of Johnson & Johnson $JNJ

WoodTrust Financial Corp cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the 3rd quarter, Holdings Channel reports. The fund owned 69,311 shares of the company’s stock after selling 2,216 shares during the period. Johnson & Johnson accounts for about 2.2% of WoodTrust Financial Corp’s investment portfolio, making the stock its 15th biggest position. WoodTrust Financial Corp’s holdings in Johnson & Johnson were worth $18,349,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Outlook Capital Management LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $28,000. Matrix Trust Co increased its holdings in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $43,000. Hyposwiss Advisors SA acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $42,000. Finally, Polaris Financial Partners purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at approximately $56,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 87,569 shares of company stock valued at $23,064,544 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported strong two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra) in moderate-to-severe plaque psoriasis. Nearly three-quarters of patients achieved clear or almost clear skin after two years, while the treatment maintained a favorable safety profile. The data support ICOTYDE’s potential as a differentiated oral psoriasis therapy and could strengthen JNJ’s future pharmaceutical growth. Johnson & Johnson ICOTYDE two-year results
• Positive Sentiment: Guggenheim reaffirmed its Buy rating, while Morgan Stanley also issued a Buy rating. The analyst support adds to the positive sentiment surrounding JNJ’s earnings outlook and pipeline investments. Guggenheim reaffirms Buy rating
• Positive Sentiment: Several articles highlighted JNJ’s established dividend-growth record and viewed the company as a relatively dependable income investment. That defensive appeal may attract investors seeking stability ahead of quarterly results. Healthcare Dividend Aristocrats
• Neutral Sentiment: JNJ is approaching its third-quarter earnings report. Analysts expect strong drug sales and contributions from newer launches, but investors will focus on whether Stelara biosimilar competition and Medical Technology weakness affect growth. J&J Q3 earnings outlook
• Negative Sentiment: JNJ faces a longer-term patent-cliff risk as exclusivity for major cancer drugs Imbruvica and Darzalex approaches expiration, potentially pressuring pharmaceutical revenue unless pipeline products and acquisitions offset the loss. Johnson & Johnson patent cliff
• Negative Sentiment: Boston Scientific is suing JNJ subsidiary Atraverse over alleged patent infringement involving the Hotwire cardiology system, seeking an injunction and damages. The case introduces potential legal costs and disruption for the Medical Technology business. Boston lawsuit against J&J subsidiary

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $4.77 during midday trading on Friday, hitting $261.25. The company’s stock had a trading volume of 1,960,164 shares, compared to its average volume of 7,940,997. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The firm’s fifty day moving average price is $265.73 and its 200-day moving average price is $248.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $629.60 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.59 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the prior year, the business earned $2.77 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 11.3 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Weiss Ratings raised shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Johnson Rice restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Finally, Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $276.22.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.